H 89 2HCl: Potent and Selective PKA Inhibitor for Precision cAMP Pathway Research

Executive Summary: H 89 2HCl (B2190) is a potent and selective small-molecule inhibitor of protein kinase A (PKA), exhibiting a Ki of 48 nM in cell-free assays [APExBIO]. It demonstrates approximately 10-fold selectivity for PKA over PKG and greater than 500-fold selectivity over other kinases, including PKC, MLCK, and CaMKII [Wang et al., 2021]. H 89 2HCl does not alter intracellular cyclic AMP concentrations, making it a valuable tool for dissecting cAMP/PKA signaling. Its robust inhibition of PKA-dependent phosphorylation is validated in multiple models, notably in forskolin-stimulated PC12D cells and in studies of osteoclastogenesis. The compound is supplied by APExBIO as a stable solid research reagent, intended for scientific use only.

Biological Rationale

cAMP-dependent protein kinase A (PKA) is a central mediator of intracellular signaling. It regulates diverse processes such as gene expression, neuronal differentiation, metabolism, and bone remodeling [Wang et al., 2021]. Dysregulation of PKA signaling is implicated in neurodegenerative diseases, cancer, and metabolic bone disorders. Precise chemical inhibition of PKA, without affecting upstream cAMP levels or off-target kinases, is essential for mechanistic studies and for validating therapeutic hypotheses.

H 89 2HCl (N-(2-(p-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide dihydrochloride) was developed to fill this need. Its selectivity profile enables researchers to attribute phenotypic changes directly to PKA inhibition. This is especially valuable in complex signaling contexts, such as dopamine-regulated osteoclast differentiation, where cAMP/PKA/CREB signaling mediates critical gene expression programs [Wang et al., 2021].

Mechanism of Action of H 89 2HCl

H 89 2HCl inhibits PKA by binding competitively to the ATP-binding site of the catalytic subunit. This blocks phosphorylation of downstream substrates in a concentration-dependent manner. The compound exhibits a Ki of 48 nM for PKA in cell-free assays [APExBIO]. It demonstrates roughly 10-fold higher affinity for PKA compared to PKG and at least 500-fold selectivity over kinases such as PKC, MLCK, CaMKII, and casein kinase I/II.

H 89 2HCl also inhibits several other kinases at higher concentrations, including S6K1 (IC50 ~80 nM), MSK1, ROCKII, PKBα, and MAPKAP-K1b (IC50 up to 2800 nM). Importantly, in cellular models, H 89 2HCl suppresses PKA-dependent phosphorylation without altering cAMP levels. For example, in PC12D pheochromocytoma cells, it inhibits forskolin-induced neurite outgrowth and histone IIb phosphorylation [APExBIO].

Evidence & Benchmarks

• H 89 2HCl inhibits PKA with a Ki of 48 nM under cell-free conditions, demonstrating high potency (APExBIO).
• Shows ~10-fold selectivity for PKA over PKG, and >500-fold selectivity over PKC, MLCK, CaMKII, and casein kinase I/II, confirming robust kinase discrimination (APExBIO).
• In PC12D cells, H 89 2HCl suppresses forskolin-induced neurite outgrowth and histone IIb phosphorylation in a dose-dependent manner, without affecting cAMP levels (Wang et al., 2021).
• In osteoclastogenesis models, H 89 2HCl blocks cAMP/PKA/CREB pathway activation, reducing CREB phosphorylation and downstream osteoclast marker expression (Wang et al., 2021).
• Compound is soluble at ≥51.9 mg/mL in DMSO, but insoluble in water and ethanol, facilitating high-concentration stock preparation for in vitro work (APExBIO).

For additional comparative and workflow data, see H 89 2HCl: Precision PKA Inhibition for Next-Gen Disease (this article extends the systems biology perspective by providing new molecular selectivity data and solubility benchmarks).

For a troubleshooting and workflow-focused guide, compare H 89 2HCl: Potent PKA Inhibitor for Precision cAMP Pathway Research. This piece is expanded here with updated selectivity and application boundaries.

Applications, Limits & Misconceptions

H 89 2HCl is widely applied in:

• Dissecting the role of PKA in cAMP-dependent signaling cascades in neuronal, bone, and cancer cell models.
• Studying dopamine-mediated suppression of osteoclast differentiation via the cAMP/PKA/CREB axis (Wang et al., 2021).
• Validating drug targets and pathway dependencies in neurodegenerative disease models and cancer research.

However, H 89 2HCl also inhibits several kinases at higher concentrations. Careful titration and appropriate controls are necessary to attribute observed effects specifically to PKA inhibition.

Common Pitfalls or Misconceptions

• Not a PKA-only inhibitor: At high concentrations, H 89 2HCl can inhibit S6K1, MSK1, ROCKII, PKBα, and MAPKAP-K1b (IC50: 80–2800 nM).
• Does not lower cAMP: H 89 2HCl does not affect intracellular cAMP levels, so cAMP-mediated but PKA-independent events are not blocked.
• Not suitable for in vivo diagnostic use: The compound is for research use only, not for clinical or diagnostic applications.
• Solubility limitations: Insoluble in water and ethanol; must be prepared in DMSO for experimental use.
• Stability: Stock solutions degrade over time; use immediately after preparation and store solid at –20°C.

For a detailed mechanistic discussion and translational guidance, see Strategic Modulation of cAMP/PKA Signaling: Mechanistic Insights. This article updates previous analyses with new selectivity evidence and workflow recommendations.

Workflow Integration & Parameters

H 89 2HCl is supplied as a solid (molecular weight: 519.28) by APExBIO (product page). For in vitro use, dissolve in DMSO at concentrations ≥51.9 mg/mL. Avoid using water or ethanol due to insolubility. Store the solid at –20°C and prepare fresh solutions immediately before use to avoid hydrolysis or degradation.

• For kinase assays, use concentrations in the 10–100 nM range for selective PKA inhibition.
• For cellular models, titrate to the lowest effective dose to minimize off-target effects.
• Include vehicle (DMSO) and non-PKA-specific inhibitor controls where possible.

Conclusion & Outlook

H 89 2HCl is a gold-standard research tool for precise and selective inhibition of PKA, enabling high-resolution studies of cAMP/PKA pathway function in health and disease. Its well-characterized selectivity, robust performance, and compatibility with routine workflows make it essential for modern signal transduction research. Future work may further refine its application in translational models and combinatorial pathway interrogation. For complete technical specifications, visit the APExBIO H 89 2HCl product page.